 Microbot Medical Inc. MBOT, a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that it has entered into definitive agreements with certain institutional investors for the purchase in a registered direct offering of 912,858 shares of its common stock, at a purchase price per share of 10.50, priced at-the-market under Nasdaq rules. The gross proceeds to Microbot, before deducting placement agent fees and other offering expenses, are expected to be approximately 9.59 million. Microbot currently intends to use the net proceeds from this offering for the continuous development and regulatory activities for its SCS device for the treatment of hydrocephalus and NPH; continue the development of the Companys LIBERTY robotic system, including its expansion through addition of complementary assets to it either through internal development, in-license or acquisitions; expand and develop additional applications deriving from its existing IP portfolio, either through internal development, in-license or acquisition; and for working capital and other general corporate purposes. 